A B S T R A C T In a previous paper, we showed that the abnormality of ristocetin-induced platelet aggregation in platelet-rich plasma in 10 patients with von Willebrand's disease could be corrected by a factor in normal plasma that was present in the same fractions as factor VIII procoagulant activity (antihemophilic factor, AHF, VIIIAHF) when prepared by chromatography on BioGel 5 M (Bio-Rad Laboratories, Richmond, Calif.). This observation suggests that patients with this disorder are deficient in a plasma factor, associated with the factor VIII molecule, that is necessary for normal platelet function. In the present paper, we describe, an assay for this factor, the von Willebrand factor (VIIIvwF), based on the observation that a log-log relationship exists between the amount of ristocetin-induced aggregation of washed, normal platelets and the concentration of normal plasma present in the test system. We assayed the activity of VIIIvwF as well as antihemophilic factor procoagulant activity (VIIIAHF) and factor VIII antigen (VIIIAGN) 
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INTRODUCTION

METHODS
Terminology. In the present paper, antihemophilic factor procoagulant activity will be referred to as VIIIAHF.
The factor in plasma that is necessary for ristocetininduced platelet aggregation and that, as will be shown, is deficient in von Willebrand's disease, is referred to as VIIIVWF, the von W\illebrand factor. The antigens on the factor VIII molecule that are identified by rabbit anti-VIII are designated as VIIIAGN. The term "factor VIII" will be used nonspecifically to refer to the presumed molecular species in normal plasma on which the three activities cited above are located. Patients. 15 unrelated patients with von Willebrand's disease were studied. The typical findings of a decreased VIIIAHF level, prolonged bleeding time, and decreased retention of platelets in glass bead filters (5) were obtained in all cases. Most of the patients have been the subjects of previous studies (1, (3) (4) (5) . 10 patients with classical severe hemophilia had VIIIAHF levels of less than 1 U/100 ml, and a patient with congenital afibrinogenemia was also studied. Control subjects were normal hospital personnel, ages 19-45.
Buffers. Tris2-buffered saline, pH 7.3, was prepared by mixing one part of 0.25 M Tris, pH 7.3 with two parts of 0.85% NaCl (Tris-saline). Tris-buffered EDTA contained 1% Na, EDTA3 in Tris-saline, pH 7.3.
Platelet suspensions. Venous blood was mixed with 1/10 volume of 1% Na2 EDTA and centrifuged at 20'C to obtain platelet-rich plasma (PRP) as previously described 2 Tris-(hydroxymethyl) iminomethane.
Na2 ethylene diaminetetraacetate.
(1 Platelet aggregation. Platelet aggregation in the platelet suspension described above was studied in the aggregometer (1) . The test system consisted of 1.0 ml of the 1% platelet suspension + 0.6 ml of Tris-saline + 0.4 ml of either plasma, dilutions of plasma, semipurified factor VIII or Tris-saline + 0.1 ml of a solution of ristocetin (Abbott Laboratories, North Chicago, Ill., 25 mg/ml in Tris-saline). The degree of platelet aggregation was expressed as percent change in OD (1). Assay of VIIIAHF and VIIIAGN. VIIIAHF was assayed in duplicate on freshly drawn plasma by a one-stage kaolinactivated partial thromboplastin time method, as previously described (6) . Activity was expressed as units per 100 ml (1) . The plasmas were then frozen in aliquots at -60'C in plastic containers for subsequent assay of VIIIVWF and VIIIAGN. VIIIAGN was measured using a radioimmunoassay that has been previously described (7) . The method for assaying VIIIVWF activity is described under Results.
Reference plasmas. Reference plasma for the VIIIAHF assays consisted of a pool of freshly drawn plasmas from four to seven healthy, male laboratory and professional personnel previously found to have VIIIAHF activities of 90-115 U/100 ml when assayed against a pool of 20 normal donors. The pooled reference plasma was designated to have an VIIIAHF activity of 100 U/100 ml. Reference plasma for the VIIIVWF assays was obtained by pooling the plasmas of these seven normal subjects in aliquots at -60'C. The activity of the VIIIvwF appeared to be quite stable in plasmas stored at -600C. Specimens of plasma from four normal subjects that had been frozen at -60'C for 1 yr had VIIIvwF activities that were within 10% of those in freshly drawn plasmas from the same subjects. A reference plasma for determination of VIIIAGN content was prepared by pooling plasmas from 10 normal donors (different from those used for the reference plasma in the VIIIAHF and VIIIVWF assays) in aliquots stored at -70'C for no longer than 2 mo (7). The pooled plasma of the seven normal subjects used for the VIIIAHF and VIIIvwF assays contained 115 VIIIAGN U/100 ml. 1 U of VIIIAGN is defined as the content present in one ml of pooled, normal human plasma (7) .
Agarose gel chromatography. Cryoprecipitate obtained from 40 ml of plasma was chromatographed on Bio-Gel 5 M as previously described (1) .
Antibodies to factor VIII. The monospecific rabbit antibody, prepared by immunizations with purified human factor VIII (8) and the plasma from a hemophiliac with a circulating antibody to VIIIAHF (human anti-VIII) were the same as in a previous study (1) . Incubation of 0.9 ml of normal human plasma with 0.1 ml of rabbit or human anti-VIII for 30 min at 370C reduced the VIIIAHF activity from 110 U/100 nil to 7 and 2.5 U/100 ml, respectively.
Statistical methods. Comparison between groups foreach of the three variables VIIIAHF, VIIIAGN, and VIIIvwr was performed by the Student's t test (9) . Equations of the regression lines for pairs of the three variables were obtained by the method of least squares (9) and segments of these lines were drawn within the limits of the experimental data. The slopes were compared with each other by the use of F tests (10) . Correlation coefficients for pairs of the variables were compared by Fisher's Z transformation (11) .
RESULTS
Aggregation of washed platelets
Washed normal platelets, studied immediately after their preparation, showed little or no (1-5%) aggregation after addition of ristocetin in a final concentration of 1.25 mg/ml. In platelet suspensions that were allowed to remain at room temperature for several hours during the day, aggregation by ristocetin sometimes occurred. Occasionally this amounted to about 20% aggregation and could be completely eliminated by addition of a rabbit antibody to factor VIII. Ristocetin-induced aggregation never occurred in washed platelets from patients with von Willebrand's disease that had been kept at room temperature for a similar period of time. These findings suggest that factor VIII, which is necessary for ristocetin-induced aggregation (see below), is removed from the platelets by repeated washing but that some remains with the platelet and is subsequently made available.
Plasma requirement for ristocetin-induced aggregation
Requirement for a factor present in plasma. Ristocetin only aggregated freshly prepared washed platelets in the presence of plasma. To determine the relationship between the degree of aggregation and the amount of plasma, we studied ristocetin-induced aggregation in the presence of various dilutions of plasma. The platelet aggregation curves obtained for a typical experiment are depicted in Fig. 1 and demonstrate that the degree of aggregation decreased with increasing dilutions of plasma. A plot of the amount of platelet aggregation vs. plasma dilution consistently gave a straight line on loglog paper (Fig. 2) .
Evidence that the plasma factor is associated with factor VIII. Fractions that eluted with VIIIArnr after chromatography of normal cryoprecipitate on Bio-Gel 5 M promoted ristocetin-induced aggregation of washed, normal platelets (Table I ). The ability of this semipurified factor VIII or of plasma to support ristocetin-induced aggregation was inhibited by incubation with a rabbit antibody to factor VIII, but was not abolished by a human anti-VIII that inhibits VIIIAHF procoagulant activity ( Table I ). As indicated in Methods, this factor in normal plasma that is necessary for ristocetininduced aggregation of washed normal platelets will be referred to as the von Willebrand factor VIIIvwF.
Assay of the von Willebrand factor (VIIIvwF )
Pooled normal plasma (see Methods) was designated as having 100 U/100 ml VIIIvwF activity, and serial dilutions of this plasma were used to obtain a line on loglog paper that related plasma concentrations of VIIIvwF to the degree of ristocetin-induced platelet aggregation (see Fig. 2 Ristocetin-induced aggregation of washed platelets was determined in the presence of serial dilutions of pooled normal plasma, as in Fig. 1 . Undiluted plasma was arbitrarily designated as having a VIIIVwF activity of 100 U/100 ml and the relationship between platelet aggregation (percent change in OD) and the activity of VIIIVWF is shown.
a new standard curve was determined on each day that the assay was performed.
Assays of VIIIVWF, VIIIAHF, and VIIIAGN in normal subjects, patients with von Willebrand's disease and hemophilic patients (Table II) The activity of VIIIvwF was decreased in all patients with von Willebrand's disease, and the average VIIIvwF level in the patients with von Willebrand's disease was significantly decreased (18.6 U/100 ml) compared with the mean value obtained in normal subjects (94.7 U/100 ml) (P < 0.001). As expected, VIIIAGN and VIIIAHF were also significantly decreased in these patients. Both VIIIvwF and VIIIAGN were normal or slightly increased in 14 patients with hemophilia. These were also normal in one patient with congenital afibrinogenemia.
Interrelationships between the three variables, VIIIVWF, VIIIAHF, and VIIIAGN The correlation matrices for the three groups of subjects are presented in Table III . In the normal subjects, there was a high degree of correlation between all three pairs of variables (r 0.80). A similar and somewhat higher correlation coefficient was found in the patients with von Willebrand's disease (r~0.90). The correlation coefficient between VIIIAGN and VIIIvwi in the hemophiliacs was smaller (r= 0.58), but not significantly different from those in the other two groups. The x2' for this comparison was 6 (5, 16) and an abnormality in ristocetin-induced platelet aggregation (1, 17) and both of these in vitro defects are also corrected by plasma or cryoprecipitate (1, 4 over, the level of this factor correlated well with the degree of their hemostatic defect; the longer the bleeding time, the lower was the level of this "von Willebrand" factor (VIIIvwr). The correlation of VIIIvwF activity with the bleeding time appeared to be better than that of the other two factor VIII variables studied (Fig. 6) . It is entirely plausible that this factor that is necessary for ristocetin-induced platelet aggregation in vitro may also be the anti-bleeding factor that is deficient in von Willebrand's disease. The assay described herein may therefore provide a method for quantitatively measuring the amount of "anti-bleeding factor" in plasma and be useful for studying patients with bleeding disorders. Since patients with von Willebrand's disease are also deficient in both the antihemophilic factor procoagulant activity (VIIIAHF) and factor VIII antigen (VIIIAGN) (7, (18) (19) (20) , the presence of the von Willebrand factor on the same molecule as these other two activities should be considered. Recent studies indicate that factor VIII is a glycoprotein whose molecular weight as determined in vitro is in excess of 2 X 108 (21) (22) (23) (24) . In an accompanying paper, we showed that the abnormal ristocetininduced aggregation in von Willebrand's disease was corrected by a fraction of plasma that eluted with VIIIAHF after chromatography on a gel that excluded molecules larger than 5 X 106 (1). This corrective effect was specifically inhibited by a rabbit antibody to factor VIII. In the present study, with similar methods, we found AAGN(U/100ml) FIGURE 6 Relationship between bleeding time and VIIIvwF, VIIIAHF, and VIIIAGN in patients with von Willebrand's disease. Because bleeding time values were truncated at 60 min, regression curves could not be calculated. Among the three sets of data shown, the best curve which could be drawn visually appeared to be one depicting a relationship between the bleeding time and VIIIvwF activity.
with von Willebrand's disease are deficient in both activities. These findings suggest that patients with hemophilia produce an incomplete or dysfunctional molecule, while the defect in von Willebrand's disease may be an impaired synthesis of the entire factor VIII molecule. The reduction in still a third activity, VIIIvwF, in von Willebrand's disease is consistent with this hypothesis. In the simplest model, a decreased synthesis of the factor VIII molecule would result in a proportional decrease in VIIIAHF, VIIIAGN, and VIIIvwF. As we know very little about the synthesis of factor VIII or the molecular configuration that determines its biological and antigenic properties, it is entirely possible that some bleeding syndromes may be owing to a decreased synthesis of a factor VIII molecule that has, in addition, functional abnormalities of the sites that determine VIIIAGN, VIIIAHF, or VIIIvwr. This would be recognized as nonproportional reduction of one or more properties. The relatively greater decrease in VIIIvw1 activity in patients J. L. and A. S. may represent this kind of molecular change. Holmberg and Nilsson have recently reported that some patients thought to have von Willebrand's disease have reduced VIIIAHF levels but normal amounts of VIIIAGN (25) . As these patients have a prolonged bleeding time, this syndrome may represent a dysfunction of VIIIAHF and the von Willebrand factor even though normal amounts of the molecule are produced. Assay of VIIIvwF activity in these patients would be of interest. Another dissociation of the properties of the factor VIII molecule is recognized in patients with von Willebrand's disease who have been transfused with plasma. Bennett, Ratnoff, and Levin have reported that the delayed increase in VIIIAHF activity in these patients is not associated with a parallel increase in VIIIAGN (26) . A more satisfactory interpretation of the findings in von Willebrand's disease awaits a better understanding of the structure and function of factor VIII.
Recent studies have shown that under conditions of high salt concentration, VIIIAnF activity is detected with proteins that have a much lower molecular weight than plasma VIIIAHF (6, 27, 28) , while VIIIAGN remains with proteins that have a molecular weight in excess of 2 X 108 (29) . Although there is evidence that VIIIvwF activity is located on a site of the factor VIII molecule different from that of VIIIAHF, it is not certain that it remains with the VIIIAGN fragment after dissociation in high salt concentrations. Studies to resolve this question are in progress.
